174 related articles for article (PubMed ID: 11823542)
1. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus.
Wang X; Huang W; Mihara M; Sinha J; Davidson A
J Immunol; 2002 Feb; 168(4):2046-53. PubMed ID: 11823542
[TBL] [Abstract][Full Text] [Related]
2. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus.
Wang X; Huang W; Schiffer LE; Mihara M; Akkerman A; Hiromatsu K; Davidson A
Arthritis Rheum; 2003 Feb; 48(2):495-506. PubMed ID: 12571860
[TBL] [Abstract][Full Text] [Related]
3. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.
Mihara M; Tan I; Chuzhin Y; Reddy B; Budhai L; Holzer A; Gu Y; Davidson A
J Clin Invest; 2000 Jul; 106(1):91-101. PubMed ID: 10880052
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T lymphocytes with constitutive CD40 ligand in preautoimmune (NZB x NZW)F1 lupus-prone mice: phenotype and possible role in autoreactivity.
Lettesjö H; Burd GP; Mageed RA
J Immunol; 2000 Oct; 165(7):4095-104. PubMed ID: 11034421
[TBL] [Abstract][Full Text] [Related]
5. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition.
Schiffer L; Sinha J; Wang X; Huang W; von Gersdorff G; Schiffer M; Madaio MP; Davidson A
J Immunol; 2003 Jul; 171(1):489-97. PubMed ID: 12817034
[TBL] [Abstract][Full Text] [Related]
6. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver.
Kay MA; Meuse L; Gown AM; Linsley P; Hollenbaugh D; Aruffo A; Ochs HD; Wilson CB
Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4686-91. PubMed ID: 9114052
[TBL] [Abstract][Full Text] [Related]
7. Treatment of murine lupus with CTLA4Ig.
Finck BK; Linsley PS; Wofsy D
Science; 1994 Aug; 265(5176):1225-7. PubMed ID: 7520604
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus.
Ramanujam M; Wang X; Huang W; Schiffer L; Grimaldi C; Akkerman A; Diamond B; Madaio MP; Davidson A
J Immunol; 2004 Sep; 173(5):3524-34. PubMed ID: 15322217
[TBL] [Abstract][Full Text] [Related]
9. Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice.
Zhou YB; Ye RG; Li YJ; Xie CM; Wu YH
Autoimmunity; 2008 Aug; 41(5):395-404. PubMed ID: 18568645
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
Early GS; Zhao W; Burns CM
J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428
[TBL] [Abstract][Full Text] [Related]
11. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.
Daikh DI; Finck BK; Linsley PS; Hollenbaugh D; Wofsy D
J Immunol; 1997 Oct; 159(7):3104-8. PubMed ID: 9317105
[TBL] [Abstract][Full Text] [Related]
12. Combination CTLA4Ig and Anti-CD40 Ligand Treatment Modifies T and B Cell Metabolic Profiles and Promotes B Cell Receptor Remodeling in a Mouse Model of Systemic Lupus Erythematosus.
Raparia C; Quach TD; Zeumer-Spataro L; Choi SC; Yi Z; Zhang W; Morel L; Davidson A
J Immunol; 2023 Mar; 210(5):558-567. PubMed ID: 36645445
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
14. [New prospects for the treatment of systemic lupus erythematosus].
Iniestra Flores F; Orea Solano M
Rev Alerg Mex; 2002; 49(6):176-80. PubMed ID: 12561649
[TBL] [Abstract][Full Text] [Related]
15. Induction of autoantibody production is limited in nonautoimmune mice.
Singh RR; Ebling FM; Albuquerque DA; Saxena V; Kumar V; Giannini EH; Marion TN; Finkelman FD; Hahn BH
J Immunol; 2002 Jul; 169(1):587-94. PubMed ID: 12077292
[TBL] [Abstract][Full Text] [Related]
16. Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig.
Chu EB; Hobbs MV; Wilson CB; Romball CG; Linsley PS; Weigle WO
J Immunol; 1996 Feb; 156(3):1262-8. PubMed ID: 8558006
[TBL] [Abstract][Full Text] [Related]
17. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
[TBL] [Abstract][Full Text] [Related]
18. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death.
Wekerle T; Kurtz J; Sayegh M; Ito H; Wells A; Bensinger S; Shaffer J; Turka L; Sykes M
J Immunol; 2001 Feb; 166(4):2311-6. PubMed ID: 11160287
[TBL] [Abstract][Full Text] [Related]
19. Role of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection.
Edelmann KH; Wilson CB
J Virol; 2001 Jan; 75(2):612-21. PubMed ID: 11134274
[TBL] [Abstract][Full Text] [Related]
20. Production of high affinity autoantibodies in autoimmune New Zealand Black/New Zealand white F1 mice targeted with an anti-DNA heavy chain.
Friedmann D; Yachimovich N; Mostoslavsky G; Pewzner-Jung Y; Ben-Yehuda A; Rajewsky K; Eilat D
J Immunol; 1999 Apr; 162(8):4406-16. PubMed ID: 10201976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
